Stockscreener 앱 받기
9.26
1.59%
-0.15
시간 외 거래:
9.30
0.04
+0.43%
전일 마감가:
$9.41
열려 있는:
$9.38
하루 거래량:
5.84M
Relative Volume:
0.45
시가총액:
$10.87B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-2.9211
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+4.04%
1개월 성능:
+2.77%
6개월 성능:
-17.32%
1년 성능:
-23.34%
1일 변동 폭
$9.22
$9.38
1주일 범위
$8.895
$9.42
52주 변동 폭
$6.85
$13.55
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.26 | 11.04B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
150.75 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.70 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.51 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.14 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com
What data driven models say about Viatris Inc.’s futureDaily Market Momentum and Pressure Analysis - Newser
US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com
How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser
Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser
Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com
How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com
How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com
How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com
Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it
What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia
What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia
What institutions are buying Viatris Inc. stock nowUnprecedented growth rates - jammulinksnews.com
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance
Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional
Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Viatris down on late-stage trial setback for eye disorder therapy - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.20%
2.09%
자본화:
|
볼륨(24시간):